Sparks commentary - BioVersys

Healthcare

Sparks - BioVersys

More on this equity
BioVersys (SIX: BIOV) announces journal publication of Phase I BV100 data
Published by Arron Aatkar, PhD

BioVersys has announced the publication of Phase I data for its lead asset, BV100, in the Journal of Antimicrobial Agents and Chemotherapy. The drug candidate is currently being investigated in Phase III for hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia (VABP) or bloodstream infections, employing a similar trial design to the prior successful Phase II trial in VABP. The Phase III readout is anticipated in H227.